CTSS and neoplasm: Among these, cathepsin S (CatS) has emerged as an attractive potential target whose inhibition promises to address the immune-suppressive milieu of the tumor microenvironment (TME) [1,3,4] due to its role in the polarization of antigen-presenting cells (APC) from an M1 toward a tumor-favoring M2-phenotype.